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One of the consequences of screening for breast cancer and the
finding of non-palpable lesions is that it entails needle-localized
open breast biopsies. A large proportion of women referred,
however, has benign disease. In The Netherlands, the percentage
of these benign breast biopsies in the context of non-palpable
lesions is 35–40% (Fracheboud et al, 1998). In the USA, 60–90%
of the women referred for open breast biopsy are reported to have
benign breast disease (Opie et al, 1993; Rubin et al, 1995).
Currently, needle-localized open breast biopsy is considered to be
the gold standard diagnostic test for non-palpable breast lesions
(Burbank and Parker, 1998; Velanovich et al, 1999). Although this
procedure is accurate, has a low complication rate and can be
performed in a day care setting, most physicians and patients
consider it a traumatic one. Moreover, the procedure is expensive;
i.e. the costs associated with it represent a major proportion of
screening-induced costs (Cyrlak, 1988).
Since the introduction of advanced ultrasound and stereotactic-
guided large-core needle biopsy techniques, percutaneous breast
biopsies are increasingly replacing open biopsies (Parker, 1994;
Fuhrman et al, 1998; Teh et al, 1998). Considering the growing
body of literature dealing with these minimally invasive tech-
niques, one might be tempted to conclude that it is already time to
replace the needle-localized breast biopsy. But is the scientific
evidence adequate to justify adopting the large-core needle biopsy
technique?
Because no large randomized controlled trials are available, we
set out to review the available literature on percutaneous breast
biopsies. A meta-analysis, including well-designed, comparative
studies, was performed to assess the diagnostic accuracy of this
new procedure.
MATERIALS AND METHODS
Reference retrieval and in- and exclusion criteria
A Medline search of the English-language literature published
between 1975 and May 1999 was performed. ‘Breast’, ‘biopsy
needle’, ‘diagnosis’, ‘non(-)palpable’ (all subheadings) were used
as keywords. A cross-reference search completed the exploration.
Because the aim of this study was to assess the diagnostic
accuracy of large-core needle biopsy, publications addressing 
fine-needle aspiration were not eligible for inclusion in the meta-
analysis.
Publications were included in the meta-analysis if the pre-set
inclusion criteria were met: (1) the mammographic lesions had to
be non-palpable; (2) all histological diagnoses of large-core needle
biopsy specimens had to be confirmed by either surgical biopsy or
adequate follow-up (defined as a minimum of 2 years in at least
90% of the patients); (3) the absolute number of benign and malig-
nant diagnoses had to be derivable; (4) a minimum of five large-
core needle biopsy specimens per non-palpable lesion had to be
obtained (as has been advocated by Liberman et al (1994)). A total
of 118 papers, addressing the issue of large-core needle biopsy for
non-palpable breast disease was retrieved. Twenty-five publica-
tions were comments, letters or review articles and in 50 studies,
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the object of study. Of the 43 publications addressing the diag-
nostic accuracy of large-core needle biopsy, five publications were
included in the meta-analysis (Parker et al, 1991; Elvecrog et al,
1993; Gisvold et al, 1994; Pijnappel et al, 1997; Jackman et al,
1999). (A list of the 38 excluded publications and the reasons for
exclusion is available upon request.) Thirty studies were excluded
because the histological diagnoses on needle biopsy were not
satisfactorily confirmed. Six studies were excluded because an
average of fewer than five core biopsies per lesion was obtained.
In one paper, the absolute number of non-palpable lesions was not
derivable and one paper was excluded because the absolute
number of benign and malignant lesions was not derivable. Two of
the authors (HMV and VCMK) independently extracted the data
from the studies using a standard form. In case of discrepancies
consensus was reached.
Meta-analysis of diagnostic accuracy
The diagnostic accuracy of large-core needle biopsy was assessed
using a method introduced by Burbank and Parker (1998). For this
purpose, the results of the studies were collapsed into a four by
four table. Firstly, the histological outcomes from the needle
biopsy procedures were classified according to one of the
following four categories:
1. benign breast disease (including normal breast tissue)
2. atypical ductal hyperplasia (ADH) (This category also
includes other high-risk lesions, e.g. lobular carcinoma in situ,
atypical lobular hyperplasia and radial scar. Because ADH is
the most common of these lesions, this category was named
accordingly
3. ductal carcinoma in situ (DCIS)
4. infiltrating breast cancer.
Lesions that were surgically removed were divided into the
same four categories according to the histological diagnosis.
Lesions with a benign histological large-core needle biopsy result
that were not surgically removed and that remained unchanged
during follow-up, were categorized as benign.
Then, the cells in the four by four table were initially labelled as
histological agreement cells, underestimate or overestimate cells
(Table 1). Agreement cells were defined as cells with identical
pathology at large-core needle biopsy and open biopsy or follow-
up. Cells, indicating a higher degree of pathology at large-core
needle biopsy than at open biopsy, were classified as overesti-
mates. Underestimate cells indicate a lower degree of pathology at
large-core needle biopsy than at open biopsy.
The underestimate cells were divided into three subcategories.
The DCIS underestimate rate was defined as the percentage of
DCIS lesions on large-core needle biopsy that is upgraded to inva-
sive cancer in the surgical specimen.
The ADH underestimate rate was defined as the percentage of
ADH lesions on large-core needle biopsy that is upgraded to DCIS
or invasive cancer. The reason that these outcomes were classified
as underestimates rather than misses is that a diagnosis of ADH on
large-core needle biopsy is always an indication for surgical
biopsy. Atypical ductal hyperplasia is a benign disease known to
be associated with an increased risk of breast cancer (Marshall
et al, 1997; Page et al, 1998; Tavassoli, 1998). Several studies have
already demonstrated that when ADH is diagnosed on large-core
needle biopsy, the risk of malignancy at surgical biopsy is 33–52%
(Liberman et al, 1995; Gadzala et al, 1997; Moore et al, 1997;
Fuhrman et al, 1998). Similarly, histological diagnoses of radial
scar, lobular carcinoma in situ and atypical lobular hyperplasia on
large-core needle biopsy are often associated with invasive or in
situ carcinomas (Lee et al, 1997; Liberman et al, 1997; Brown
et al, 1998; Fuhrman et al, 1998), and therefore always an indica-
tion for surgical biopsy.
The miss rate was defined as the proportion of all breast cancers
(invasive cancer and DCIS) with a diagnosis of only benign
disease on large-core needle biopsy. Accordingly, the sensitivity
rate was defined as one minus the miss rate.
The remaining overestimate and underestimate cells were then
reclassified into clinically relevant categories (Table 1). For clini-
cally relevant purposes, a diagnosis of benign disease on large-
core needle biopsy, upgraded to ADH, was reclassified as
agreement. Although the finding of ADH in a surgical specimen is
associated with an increased risk of breast cancer (Marshall et al,
1997; Page et al, 1998; Tavassoli, 1998), it does not have clinical
consequences. Moreover, ADH lesions are by definition small
(≤2 mm) (Tavassoli, 1998) and therefore the finding of ADH in 
a surgical specimen is nearly always incidental. In addition,
Burbank and Parker (1998) argue that overestimates are actually
clinically relevant agreements rather than disagreements. For
example, if large-core needle biopsy had identified invasive breast
cancer and the surgical specimen contained only fibrocystic
changes, the target lesion would still maintain the diagnosis of
invasive cancer. The lower degree of pathology seen in the open
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Table 1 Classification of large-core needle biopsy results as agreements (A), underestimates (U) and overestimates (O) and reclassification for clinical
relevance in brackets (adapted from Burbank and Parker, 1998)
Large-core needle biopsy Open biopsy/follow-up
Benign disease ADH DCIS Invasive cancer
Benign disease A U U U
(agreement) (miss) (miss)
ADH O A U U
(agreement) (ADH underestimate) (ADH underestimate)
DCIS O O A U
(agreement) (agreement) (DCIS underestimate)
Invasive cancer O O O A
(agreement) (agreement) (agreement)
ADH, atypical ductal hyperplasia; DCIS, ductal carcinoma in situ.biopsy specimen can be explained by either complete removal of
the lesion by the large-core needle biopsy (Dronkers, 1992;
Mikhail et al, 1994) or by inadequate surgical excision (lesion not
removed). Therefore, these overestimate cells were also reclassi-
fied as agreement cells. Accordingly, the reclassified agreement
rate was defined as the proportion of cells not classified as DCIS
underestimate, ADH underestimate or miss.
Underestimate rates, miss rates and reclassified agreement rates
were calculated as described above for each of the five studies as
well as pooled estimates after testing for homogeneity of the
studies using Fisher exact test (Altman, 1991).
Finally, the clinical consequences of the miss rate of the large-
core needle biopsy technique were evaluated for different disease
prevalences. For this purpose, the predictive value of a benign
biopsy result was calculated for different disease prevalences,
applying the following formula:
Risk of malignancy despite benign histological diagnosis on
large-core needle biopsy = 
(12sensitivity)*prevalence/((12sensitivity)*prevalence +
specificity*(12prevalence))
As discussed previously, a malignant diagnosis on large-core
needle biopsy followed by a benign diagnosis of the open biopsy
specimen was not considered as an overestimate or false-positive
result. We therefore agreed on a specificity rate of the large-core
needle biopsy of 1.0. Statistics were performed using Statistical
Package for Social Sciences 6.0 (SPSS Inc. Chicago, IL, USA).
Exact confidence intervals were calculated.
RESULTS
Table 2 shows the data obtained from the five papers. In all studies,
stereotactic guidance was applied. Pijnappel et al (1997) used
ultrasound guidance in addition to stereotactic guidance in three
cases (4%). Stereotactic biopsy was performed with the patient in
prone position by using a 14-gauge needle and a long throw biopsy
gun. In four studies all histological diagnoses of large-core needle
biopsy specimens were confirmed by additional open biopsy and
generally these two procedures took place on the same day (Parker
et al, 1991; Elvecrog et al, 1993; Gisvold et al, 1994; Pijnappel et
al, 1997). In the study of Jackman et al (1999), 295 patients (61%)
with a benign diagnosis on large-core needle biopsy did not
undergo immediate open biopsy, but mammographic follow-up.
During follow-up, repeat biopsy was performed in 36 patients. Of
the remaining 259 patients, 96% was followed for at least 2 years
and the median follow-up period was 55 months. Lesions with
discrepancy between mammography and histological diagnosis on
large-core needle biopsy were surgically removed. Also, patients
with a diagnosis of atypical ductal or lobular hyperplasia, radial
scar or carcinoma (invasive and in situ) on large-core needle
biopsy were planned for surgery.
A total of 865 large-core needle biopsy procedures was
performed and 56% was carried out in the context of one study
(Jackman et al, 1999). In four studies the percentage of lesions
with microcalcifications was reported (Elvecrog et al, 1993;
Gisvold et al, 1994; Pijnappel et al, 1997; Jackman et al, 1999)
which varied from 21 to 48%. The malignancy rate varied from 23
to 57% and four studies reported that 9–40% of all malignant
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Table 2 Characteristics of the studies included in meta-analysis
First author Imaging Needle Consecutive Mean age Number of biopsy Proportion Proportion DCIS Proportion DCIS of all Complications
year of publication technique diameter patients procedures (n) microcalci- and invasive malignancies
fications cancer
Parker 1991 Stereotaxis 14-gauge ? ? 102 ? 23% 9% 0
Elvecrog 1993 Stereotaxis 14-gauge Consa ? 100 26% 35% 11% 1
Gisvold 1994 Stereotaxis 14-gauge Non-consa 59 104 33% 43% ? 1
Pijnappelb 1997 Stereotaxis 14-gauge Consa 55 76 21% 57% 30% 0
and ultrasound
Jackman 1999 Stereotaxis 14-gauge Consa 55 483 48% 31% 40% ?
(median)
aCons = consecutive patients. bAll studies were conducted in the USA, except for the study of Pijnappel et al, which was conducted in The Netherlands.
Table 3 Number of DCIS and ADH and underestimate rates (95% CI)
Study DCIS on needle DCIS-lesions DCIS ADH on needle ADH lesions ADH underestimate
biopsy upgraded to underestimate rate biopsy upgraded to rate
invasive cancer (%) carcinoma (%)
Parker 1991 2 0 0 (0–84) ? ? ?
Elvecrog 1993 ? ? ? 6 0 0 (0–52)
Gisvold 1994 ? ? ? 2 1 50 (13–99)
Pijnappel 1997 13 3 23 (5.0–54) 7 1 14 (4.0–58)
Jackman 1999 56 8 14 (6.0–26) 30 16 53 (34–72)
Pooled 71 11 15 (8.0–26) 45 18 40 (26–56)
DCIS, ductal carcinoma in situ; ADH, atypical ductal hyperplasia.lesions was DCIS only. The number of complications was low;
only one haematoma and one infection (which also might have
been caused by the open biopsy procedure) were described.
Table 3 presents the DCIS and ADH underestimate rates. The
DCIS underestimate rate was derivable for three of five studies
and the pooled DCIS underestimate rate of these three studies was
15% (95% CI 8–26%). The ADH underestimate rate could be
derived for four studies and the pooled ADH underestimate rate
was 40% (95% CI 26–56%).
In Table 4 the sensitivity rate of large-core needle biopsy for all
studies was calculated. Of 307 carcinomas, eight were diagnosed
as benign by large-core needle biopsy (3%). Consequently, the
sensitivity rate was 97% (95% CI 95–99%).
The reclassified agreement rate was derivable for two studies. In
the study of Pijnappel et al (1997), there was clinically relevant
discrepancy in five of 76 cases (one ADH underestimate, three
DCIS underestimates and one miss), resulting in a reclassified
agreement rate of 93% (95% CI 85–98%). In the study of Jackman
et al (1999) there were 26 discrepancies (16 ADH underestimates,
eight DCIS underestimates and two misses) on a total of 483
lesions, resulting in a reclassified agreement rate of 95% (95% CI
92–97) in this study. Combining the results of these two studies
gives rise to a pooled reclassified agreement rate of 94% (95% CI
92–96%). 
Table 5 shows the risk of malignancy despite benign large-core
needle biopsy result for different assumptions of breast cancer
prevalences. In a population with a low prevalence of malignancy
of e.g. 20% (i.e. USA), the probability of a carcinoma being
present despite benign needle biopsy result is low (0.6%). In
Western Europe, however, 60–70% of the lesions detected by
screening and referred for histological biopsy turn out to be malig-
nant, due to the use of different cut-off points for referral. If in
such a setting a large-core needle biopsy reveals benign disease,
the probability of a carcinoma being present will still be 4–6%.
DISCUSSION
This meta-analysis showed that the diagnostic accuracy of large-
core needle biopsy is high. The sensitivity rate was 97% and the
reclassified agreement rate was 94%. Accordingly, large-core
needle biopsy seems to be an attractive alternative for the needle-
localized open breast biopsy.
We used the approach of Burbank and Parker (1998) for evalu-
ating the diagnostic performance of large-core needle biopsy. With
this approach, the reclassified agreement rate is not an estimate for
exact histological accordance between large-core needle biopsy
and surgical biopsy. Certain discrepancies between large-core
needle biopsy and open biopsy (e.g. fibrocystic disease on large-
core needle biopsy and ADH on surgical biopsy, or DCIS on large-
core needle biopsy and fibrocystic disease on open biopsy) were
considered as agreements. The reclassified agreement rate is there-
fore a clinically relevant and pragmatic estimate for the accor-
dance between large-core needle biopsy and actual disease status.
This estimate, however, could only be calculated for two studies.
A DCIS underestimate rate of 15% indicates that 15% of the
patients with a diagnosis of DCIS on large-core needle biopsy will
prove to have invasive breast cancer at surgery. In most of these
cases, an additional surgical procedure will then be necessary
(axillary dissection with or without re-excision). Similarly, all
patients with a diagnosis of ADH, atypical lobular hyperplasia,
lobular carcinoma in situ or radial scar on large-core needle biopsy
need to undergo open breast biopsy. Although the use of large-core
needle biopsy eventually results in a correct histological diagnosis
in these patient categories, large-core needle biopsy is an extra
diagnostic procedure as compared to the situation with open breast
biopsy as initial diagnostic procedure.
The pooled analysis showed a sensitivity rate of 97%. This
value may be overestimated due to the non-blindness of the
pathologists (Irwig et al, 1994). In four studies large-core needle
biopsy procedures as well as open biopsy procedures were
performed on the same day (Parker et al, 1991; Elvecrog et al,
1993; Gisvold et al, 1994; Pijnappel et al, 1997). Therefore,
pathologists may not have been blinded for the results of the refer-
ence standard test (open biopsy).
Moreover, 56% of all lesions were derived from the study of
Jackman et al (1999). The relatively high sensitivity rate reported
in this study has therefore substantially influenced the results of
this meta-analysis.
Cut-off points for referral after breast cancer screening differ
substantially between the USA and Europe. As a consequence,
prevalence of malignancy among women referred for breast
biopsy is approximately 20% in the USA compared to 60% in
Europe. This difference can be explained by the fact that screening
for breast cancer is more difficult in the USA than it is in Europe.
In the first place, every American woman over 40 years is advised
to undergo annual screening mammography, while in The
Netherlands breast cancer screening starts at the age of 50.
Because breast tissue is denser in younger women, screening
mammograms will be more difficult to interpret, resulting in a
lower sensitivity and specificity rate (Beemsterboer et al, 1998;
UK Trial of Early Detection of Breast Cancer Group, 1999).
Secondly, in the USA, approximately 50% of post-menopausal
women use hormone replacement therapy (HRT) (Grodstein et al,
1997), compared to only 22% in the UK (Achuthan et al, 1999).
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Table 4 Total number of malignancies (i.e. invasive and DCIS) and
sensitivity (95% CI)
Study Total number of Number of malignancies Sensitivity
malignancies missed at large-core %
needle biopsy
Parker 1991 23 1 96 (78–100)
Elvecrog 1993 35 1 97 (85–100)
Gisvold 1994 45 3 93 (82–99)
Pijnappel 1997 43 1 98 (88–100)
Jackman 1999 161 2 99 (96–100)
Pooled 307 8 97 (95–99)
Table 5 Risk of malignancy despite benign histological diagnosis on large-
core needle biopsy as a function of prevalence of malignancy (sensitivity rate
97%, specificity rate 100%)
Prevalence of malignancy (%) Risk of malignancy despite benign
needle biopsy result (%)
10 0.3
20 0.6
30 1.3
40 2.0
50 2.9
60 4.3
70 6.5HRT influences the breast parenchyma, resulting in a decreased
sensitivity and specificity rate of screening mammographies (Laya
et al, 1996).
The difference in prevalence of malignancy leaves the practical
consequences of replacing open biopsy by large-core needle biopsy
open to discussion. In the USA, the need for minimally invasive
and less expensive diagnostic tests is high because a large propor-
tion of women undergoes benign breast biopsy. The risk of breast
cancer in case of benign large-core core needle biopsy results is
small (0.6%) in a population with relatively low breast cancer
prevalence. On the contrary, in European screening settings the
higher breast cancer prevalence among referred women will result
in a relatively high risk of breast cancer in case of benign large-core
needle biopsy (4–6%). One might argue which procedure is more
effective in diagnosing breast cancer and preventing mortality of it:
a rather unselective referral of women with low disease prevalence,
worked up by the large-core needle procedure, or a more restricted
selection of women with a relatively high disease prevalence,
worked up by needle-localized open breast biopsy.
In addition, the miss rate of 3% may be reduced by identifying
other high-risk categories, besides ADH, atypical lobular hyper-
plasia, lobular carcinoma in situ and radial scars. Perhaps the
category of microcalcification lesions should be handled more
cautiously, as it has been suggested that the miss rate of stereo-
tactic large-core needle biopsy is higher for microcalcifications
than for mass lesions (Burbank and Parker, 1998).
In The Netherlands a prospective multicentre study (funded by
the Ministry of Public Health) was started at the end of 1997 to
address these issues. The study aims to include 1000 consecutive
patients with non-palpable breast lesions who will all undergo both
stereotactically guided large-core needle biopsy (14-gauge with a
long-throw biopsy gun) on a prone table and surgical breast
biopsy. Preferences of women and cost consequences will also be
taken into account.
CONCLUSION
The high sensitivity rate (97%) and high reclassified agreement
rate (94%) of the large-core needle biopsy make this technique a
promising alternative for needle-localized open breast biopsy.
However, additional research is required to elucidate limiting
factors of the technique and to decide on optimal patient selection
strategies. Without such detailed knowledge, a benign histological
diagnosis on large-core needle biopsy in countries with high
prevalence of malignancy among referred women should be
handled with caution.
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